Clinical Grade Non-Transfusable Mobilized Peripheral Blood CD34+ Stem Cells, Plerixafor, Frozen
CD34 is a glycosylated transmembrane protein and represents a well-established marker for human hematopoietic stem and progenitor cells in peripheral blood, bone marrow, cord blood, and fetal liver. CD34+ cells are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system through a process called hematopoiesis. As hematopoietic stem cells progress through hematopoiesis they generate the myeloid (monocytes, macrophages, granulocytes, megakaryocytes, dendritic cells, and erythrocytes), and lymphoid (T cells, B cells, and NK cells) lineages. The highly specialized cells that arise from hematopoietic stem cells work collaboratively in defending the body against infection and disease.
Human mobilized peripheral blood CD34+ cells are enriched from the total cell population using direct immunomagnetic anti-CD34 beads. All cell isolation components, including reagents, tubing sets, instruments, and buffers, are manufactured and controlled under an ISO 13485 certified quality system under FDA oversight. Cell culture procedures, including open manipulation of vials, final filling, and closure of finished products, are performed inside ISO 5 air quality processing chambers located within an FDA-registered cell manufacturing facility. Isolated primary cells are characterized by flow cytometry to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols. All reagents and devices used to collect and separate the cells are certified clinical grade. This item is for research use only.
|Cell and Tissue Source||Peripheral Blood|
|Product Type||Primary Cells|
|Cell Type||Stem/Progenitor Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Purity||≥85% by Flow Cytometry|
|Viability||≥80% by Flow Cytometry|
|Contains||StemSpan™ and 10% DMSO|
|Injections||240μg/kg Plerixafor the day before collection|